IL253704B - [10, 9 – dimethoxy – 3 – (2 – methylpropyl) – bh – 11h, 7h, 6h, 4h, 3h, 2h, 1h – pyrido – [ 2,1 – a ] isoquinoline – 2 – yl ] methanol and compounds and preparations and related methods - Google Patents

[10, 9 – dimethoxy – 3 – (2 – methylpropyl) – bh – 11h, 7h, 6h, 4h, 3h, 2h, 1h – pyrido – [ 2,1 – a ] isoquinoline – 2 – yl ] methanol and compounds and preparations and related methods

Info

Publication number
IL253704B
IL253704B IL253704A IL25370417A IL253704B IL 253704 B IL253704 B IL 253704B IL 253704 A IL253704 A IL 253704A IL 25370417 A IL25370417 A IL 25370417A IL 253704 B IL253704 B IL 253704B
Authority
IL
Israel
Prior art keywords
isoquinolin
pyrido
methylpropyl
dimethoxy
methanol
Prior art date
Application number
IL253704A
Other languages
English (en)
Hebrew (he)
Other versions
IL253704A0 (en
Original Assignee
Neurocrine Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neurocrine Biosciences Inc filed Critical Neurocrine Biosciences Inc
Publication of IL253704A0 publication Critical patent/IL253704A0/en
Publication of IL253704B publication Critical patent/IL253704B/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/4738Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D455/00Heterocyclic compounds containing quinolizine ring systems, e.g. emetine alkaloids, protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine
    • C07D455/03Heterocyclic compounds containing quinolizine ring systems, e.g. emetine alkaloids, protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine containing quinolizine ring systems directly condensed with at least one six-membered carbocyclic ring, e.g. protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine
    • C07D455/04Heterocyclic compounds containing quinolizine ring systems, e.g. emetine alkaloids, protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine containing quinolizine ring systems directly condensed with at least one six-membered carbocyclic ring, e.g. protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine containing a quinolizine ring system condensed with only one six-membered carbocyclic ring, e.g. julolidine
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D519/00Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
IL253704A 2015-02-06 2017-07-27 [10, 9 – dimethoxy – 3 – (2 – methylpropyl) – bh – 11h, 7h, 6h, 4h, 3h, 2h, 1h – pyrido – [ 2,1 – a ] isoquinoline – 2 – yl ] methanol and compounds and preparations and related methods IL253704B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562113316P 2015-02-06 2015-02-06
PCT/US2016/016892 WO2016127133A1 (en) 2015-02-06 2016-02-05 [9,10-dimethoxy-3-(2-methylpropyl)-1h,2h,3h,4h,6h,7h,11bh-pyrido-[2,1-a]isoquinolin-2-yl]methanol and compounds, compositions and methods relating thereto

Publications (2)

Publication Number Publication Date
IL253704A0 IL253704A0 (en) 2017-09-28
IL253704B true IL253704B (en) 2021-02-28

Family

ID=55404854

Family Applications (1)

Application Number Title Priority Date Filing Date
IL253704A IL253704B (en) 2015-02-06 2017-07-27 [10, 9 – dimethoxy – 3 – (2 – methylpropyl) – bh – 11h, 7h, 6h, 4h, 3h, 2h, 1h – pyrido – [ 2,1 – a ] isoquinoline – 2 – yl ] methanol and compounds and preparations and related methods

Country Status (12)

Country Link
US (4) US9714246B2 (enExample)
EP (1) EP3253752B1 (enExample)
JP (1) JP6755254B2 (enExample)
KR (1) KR102586138B1 (enExample)
CN (1) CN107438606B (enExample)
AU (1) AU2016215033B2 (enExample)
CA (1) CA2974540C (enExample)
ES (1) ES2960717T3 (enExample)
IL (1) IL253704B (enExample)
MX (1) MX375718B (enExample)
RU (1) RU2736509C2 (enExample)
WO (1) WO2016127133A1 (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20241046T1 (hr) 2014-01-21 2024-11-08 Neurocrine Biosciences, Inc. Antagonisti crf1 receptora za liječenje kongenitalne adrenalne hiperplazije
EP3253752B1 (en) 2015-02-06 2023-08-16 Neurocrine Biosciences, Inc. [9,10-dimethoxy-3-(2-methylpropyl)-1h,2h,3h,4h,6h,7h,11bh-pyrido-[2,1-a]isoquinolin-2-yl]methanol and compounds, compositions and methods relating thereto
WO2017075340A1 (en) 2015-10-30 2017-05-04 Neurocrine Biosciences, Inc. Valbenazine salts and polymorphs thereof
MA44127A (fr) 2015-12-23 2018-10-31 Neurocrine Biosciences Inc Procédés de synthèse pour la préparation de di(4-méthylbenzènesulfonate) de 2-amino-3-méthylbutanoate de (s)-(2r,3r,11br)-3-isobutyl-9,10-diméthoxy-2,3,4,6,7,11b-hexahydro-1h-pyrido[2,1,-a]isoquinoléin-2-yl
KR20230038601A (ko) 2017-01-27 2023-03-20 뉴로크린 바이오사이언시즈 인코퍼레이티드 특정 vmat2 억제제의 투여 방법
GB201705302D0 (en) 2017-04-01 2017-05-17 Adeptio Pharmaceuticals Ltd Pharmaceutical compositions
GB201705306D0 (en) 2017-04-01 2017-05-17 Adeptio Pharmaceuticals Ltd Pharmaceutical compositions
GB201705304D0 (en) 2017-04-01 2017-05-17 Adeptio Pharmaceuticals Ltd Pharmaceutical compositions
GB201705303D0 (en) 2017-04-01 2017-05-17 Adeptio Pharmaceuticals Ltd Pharmaceutical compositions
JOP20190239A1 (ar) 2017-04-19 2019-10-09 Neurocrine Biosciences Inc مركبات مثبطة لـ vmat2 وتركيبات منها
CA3076000A1 (en) 2017-09-21 2019-03-28 Neurocrine Biosciences, Inc. High dosage valbenazine formulation and compositions, methods, and kits related thereto
MY198713A (en) 2017-10-10 2023-09-19 Neurocrine Biosciences Inc Methods for the administration of certain vmat2 inhibitors
KR20250070134A (ko) 2017-10-10 2025-05-20 뉴로크린 바이오사이언시즈 인코퍼레이티드 특정 vmat2 억제제의 투여 방법
GB201808464D0 (en) 2018-05-23 2018-07-11 Adeptio Pharmaceuticals Ltd Pharmaceutical compounds for use in treating huntington's disease
EP3806856A1 (en) * 2018-06-14 2021-04-21 Neurocrine Biosciences, Inc. Vmat2 inhibitor compounds, compositions, and methods relating thereto
EP3836926A4 (en) 2018-08-15 2022-05-04 Neurocrine Biosciences, Inc. METHOD OF ADMINISTRATION OF CERTAIN VMAT2 INHIBITORS
EP3860599B1 (en) 2018-10-04 2024-05-15 Adeptio Pharmaceuticals Limited (+)-alpha-dihydrotetrabenazine dosage regimen for treating movement disorders
DK3984523T3 (da) 2018-12-07 2025-09-29 Neurocrine Biosciences Inc Crf1-receptorantagonist, farmaceutiske formuleringer og faste former heraf til behandling af medfødt binyrebarkhyperplasi
US10940141B1 (en) 2019-08-23 2021-03-09 Neurocrine Biosciences, Inc. Methods for the administration of certain VMAT2 inhibitors
CN114502162B (zh) * 2019-09-27 2025-03-28 纽罗克里生物科学有限公司 Crf受体拮抗剂及使用方法
CR20230448A (es) 2021-03-22 2023-10-27 Neurocrine Biosciences Inc Inhibidores de vmat2 y métodos de uso

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS54125699A (en) * 1978-03-17 1979-09-29 Nippon Chemiphar Co Ltd Preparation of ( ) dihydroprotoemetine
WO2005000846A1 (en) * 2003-06-20 2005-01-06 F.Hoffmann-La Roche Ag Hexahydropyridoisoqinolines as dpp-iv inhibitors
AU2007317242B2 (en) * 2006-11-08 2013-08-01 Neurocrine Biosciences, Inc. Substituted 3-isobutyl-9, 10-dimethoxy-1,3,4,6,7,11B-hexahydro-2H-pyrido[2,1-a] isoquinolin-2-ol compounds and methods relating thereto
RU2339363C2 (ru) 2006-12-28 2008-11-27 Лидия Ибрагимовна Гайсанова Мазь "бунхо", обладающая противовоспалительным и регенерирующим действием
WO2015120317A1 (en) * 2014-02-07 2015-08-13 Neurocrine Biosciences, Inc. Pharmaceutical compositions comprising an antipsychotic drug and a vmat2 inhibitor and uses thereof
EP3253752B1 (en) 2015-02-06 2023-08-16 Neurocrine Biosciences, Inc. [9,10-dimethoxy-3-(2-methylpropyl)-1h,2h,3h,4h,6h,7h,11bh-pyrido-[2,1-a]isoquinolin-2-yl]methanol and compounds, compositions and methods relating thereto

Also Published As

Publication number Publication date
NZ733899A (en) 2024-01-26
MX375718B (es) 2025-03-06
JP6755254B2 (ja) 2020-09-16
IL253704A0 (en) 2017-09-28
US20160289226A1 (en) 2016-10-06
CN107438606B (zh) 2020-09-18
US20200262834A1 (en) 2020-08-20
US9714246B2 (en) 2017-07-25
EP3253752A1 (en) 2017-12-13
BR112017016934A2 (pt) 2018-04-03
RU2017130514A (ru) 2019-03-07
US9988382B2 (en) 2018-06-05
US20170349586A1 (en) 2017-12-07
WO2016127133A1 (en) 2016-08-11
JP2018504437A (ja) 2018-02-15
KR102586138B1 (ko) 2023-10-05
KR20170113620A (ko) 2017-10-12
RU2736509C2 (ru) 2020-11-17
RU2017130514A3 (enExample) 2019-08-27
ES2960717T3 (es) 2024-03-06
US11053242B2 (en) 2021-07-06
EP3253752B1 (en) 2023-08-16
US20180273533A1 (en) 2018-09-27
CA2974540A1 (en) 2016-08-11
AU2016215033A1 (en) 2017-08-10
CN107438606A (zh) 2017-12-05
CA2974540C (en) 2023-09-26
AU2016215033B2 (en) 2020-06-25
MX2017010062A (es) 2017-11-01
EP3253752C0 (en) 2023-08-16

Similar Documents

Publication Publication Date Title
IL253704B (en) [10, 9 – dimethoxy – 3 – (2 – methylpropyl) – bh – 11h, 7h, 6h, 4h, 3h, 2h, 1h – pyrido – [ 2,1 – a ] isoquinoline – 2 – yl ] methanol and compounds and preparations and related methods
GB2550986B (en) Planetary gearsets
IL252311B (en) 4-oxo-4,3-dihydro-3,2,1-benzotriazines as G protein-coupled receptor modulators 139
IL240434A0 (en) Bicyclo 3,2-benzodiazepines and spirocyclically converted 3,2-benzodiazepines
SG11201703479SA (en) Substituted 2,4 diamino-quinoline as new anticancer agents
IL253844A0 (en) A new C-3 triterpenone with a c-17 reverse amide history as hiv inhibitors
EP3172324A4 (en) 5'-triphosphate oligoribonucleotides
ZA202000970B (en) Pentacyclic compound
PT3478664T (pt) Métodos para a síntese de dextrometorfano deuterado
EP3241572A4 (en) Degradable iron-base alloy support
IL252986B (en) 5,3-diaminopyrazole kinase inhibitors
WO2016025473A3 (en) Synthesis of tetracyclic flavonoids
LT3169665T (lt) Pakeistieji aza-spiro(4.5)dekano dariniai
EP3200780A4 (en) Hydrogen peroxide-activated compounds as selective anti-cancer therapeutics
EP3221072A4 (en) Presintered brazing
GB201702182D0 (en) Gearsets
GB201701683D0 (en) Gearsets
GB201500288D0 (en) John's closet
PT3445377T (pt) Composições para a pele
AU2016902359A0 (en) "back buddy"
GB201419059D0 (en) The closet number 2
GB201511757D0 (en) The "i-wheel"

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed